Search

Your search keyword '"Montcuquet, A"' showing total 88 results
Start Over Author "Montcuquet, A" Publisher elsevier bv
88 results on '"Montcuquet, A"'

4. “Co-encapsulation of Immunosuppressive Drug with Anti-inflammatory Molecule in Pickering Emulsions as a Novel Therapeutic Approach for Inflammatory Dermatoses”

Author

Sintès, Maxime, primary, Kovjenic, Petra, additional, Haine (Hablal), Liasmine, additional, Serror, Kevin, additional, Beladjine, Mohamed, additional, Parietti (Montcuquet), Véronique, additional, Delagrange, Marine, additional, Ducos, Bertrand, additional, Bouaziz, Jean-David, additional, Boccara, David, additional, Mimoun, Maurice, additional, Bensussan, Armand, additional, Bagot, Martine, additional, Huang, Nicolas, additional, and Michel, Laurence, additional

Published
2024
Full Text
View/download PDF

5. Gynaecological follow-up for women of reproductive age with multiple sclerosis: The GYNESEP study

Author

Renaud, Juliette, primary, Buissonnière, Pauline, additional, Dulau, Cécile, additional, Deloire, Mathilde, additional, Hontarrede, Florian, additional, Montcuquet, Alexis, additional, Chansel-Debordeaux, Lucie, additional, Hocké, Claude, additional, Ouallet, Jean-Christophe, additional, Ruet, Aurélie, additional, and Bernard, Valérie, additional

Published
2024
Full Text
View/download PDF

6. Paradigm shifts in multiple sclerosis management: Implications for daily clinical practice

Author

B, Bourre, O, Casez, J, Ciron, A, Gueguen, A, Kwiatkowski, X, Moisset, A, Montcuquet, and X, Ayrignac

Subjects
Neurology, Neurology (clinical)
Abstract

Multiple sclerosis (MS) is the most common chronic inflammatory neurological disease. The emergence of disease-modifying therapies (DMTs) has greatly improved disease activity control and progression of disability in MS patients. DMTs differ in their mode of action, route of administration, efficacy, and safety profiles, offering multiple options for clinicians. Personalized medicine aims at tailoring the therapeutic strategy to patients' characteristics and disease activity but also patients' needs and preferences. New therapeutic options have already changed treatment paradigms for patients with active relapsing MS (RMS). The traditional approach consists in initiating treatment with moderate-efficacy DMTs and subsequently, escalating to higher-efficacy DMTs when there is evidence of clinical and/or radiological breakthrough activity. Recent real-world studies suggest that initiation of high-efficacy DMTs from disease onset can improve long-term outcomes for RMS patients. In this article, we review different treatment strategies and discuss challenges associated with personalized therapy.

Published
2023
Full Text
View/download PDF

8. Infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society

Author

Papeix, C., primary, Donze, C., additional, Lebrun-Frénay, C., additional, Papeix, C., additional, Donzé, C., additional, Laplaud, D., additional, Thouvenot, E., additional, Ayrignac, X., additional, Pourcher-Martinez, V., additional, Zéphir, H., additional, de Seze, J., additional, Michel, L., additional, Bensa, C., additional, Cara-Dalliere, C., additional, Guen-noc, A.M., additional, Casez, O., additional, Maarouf, A., additional, Bourre, B., additional, Kwiatkowski, A., additional, Cohen, M., additional, Maillart, E., additional, Collongues, N., additional, Louapre, C., additional, Androdias, G., additional, Guegen, A., additional, Audoin, B., additional, Mattey, G., additional, Bernady, P., additional, Faucheux, J.M., additional, Labauge, P., additional, Meckies, C., additional, Stankoff, B., additional, Tourniaire, P., additional, Dinh, A., additional, Guennoc, A.M., additional, Durnad-Dubief, F., additional, Wiertlewski, S., additional, Derache, N., additional, Le page, E., additional, Pittion, S., additional, Vukusic, S., additional, Clavelou, P., additional, Heinzlef, O., additional, Colamarino, R., additional, Planque, E., additional, Rico, A., additional, Sheiber nogueira, C., additional, de Seze, M., additional, Ciron, J., additional, Alchaar, H., additional, Bensmail, D., additional, Biotti, D., additional, Branger, P., additional, Brochet, B., additional, Castan, B., additional, Creange, A., additional, Creisson, E., additional, DeBroucker, T., additional, Depaz, R., additional, Douay, X., additional, Dulau, C., additional, Faucher, M., additional, Fournier, M., additional, Fromont, A., additional, Gallien, P., additional, Gout, O., additional, Grimaud, J., additional, Hervé, Y., additional, Kerbrat, A., additional, Kremer, L., additional, Lanotte, L., additional, Magy, L., additional, Mania, A., additional, Maurousset, A., additional, Moisset, X., additional, Montcuquet, A., additional, Moreau, T., additional, Morel, N., additional, Patry, I., additional, Peaureaux, D., additional, Pouget, M.C., additional, Ruet, A., additional, Saint-Val, C., additional, Stahl, J.P., additional, Taithe, F., additional, Tattevin, P., additional, Vaillant, M., additional, and Vuoto, F., additional

Published
2021
Full Text
View/download PDF

9. The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies

Author

Andersen, Johanna B, primary, Sharmin, Sifat, additional, Lefort, Mathilde, additional, Koch-Henriksen, Nils, additional, Sellebjerg, Finn, additional, Sørensen, Per Soelberg, additional, Hilt Christensen, Claudia C, additional, Rasmussen, Peter V, additional, Jensen, Michael B, additional, Frederiksen, Jette L, additional, Bramow, Stephan, additional, Mathiesen, Henrik K, additional, Schreiber, Karen I, additional, Horakova, Dana, additional, Havrdova, Eva K, additional, Alroughani, Raed, additional, Izquierdo, Guillermo, additional, Eichau, Sara, additional, Ozakbas, Serkan, additional, Patti, Francesco, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Terzi, Murat, additional, Grammond, Pierre, additional, Grand Maison, Francois, additional, Yamout, Bassem, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Boz, Cavit, additional, Trojano, Maria, additional, McCombe, Pamela, additional, Slee, Mark, additional, Lechner-Scott, Jeannette, additional, Turkoglu, Recai, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Granella, Franco, additional, Shaygannejad, Vahid, additional, Prevost, Julie, additional, Skibina, Olga, additional, Solaro, Claudio, additional, Karabudak, Rana, additional, Wijmeersch, Bart V, additional, Csepany, Tunde, additional, Spitaleri, Daniele, additional, Vucic, Steve, additional, Casey, Romain, additional, Debouverie, Marc, additional, Edan, Gilles, additional, Ciron, Jonathan, additional, Ruet, Aurélie, additional, Sèze, Jérôme D, additional, Maillart, Elisabeth, additional, Zephir, Hélène, additional, Labauge, Pierre, additional, Defer, Gilles, additional, Lebrun, Christine, additional, Moreau, Thibault, additional, Berger, Eric, additional, Clavelou, Pierre, additional, Pelletier, Jean, additional, Stankoff, Bruno, additional, Gout, Olivier, additional, Thouvenot, Eric, additional, Heinzlef, Olivier, additional, Al-Khedr, Abdullatif, additional, Bourre, Bertrand, additional, Casez, Olivier, additional, Cabre, Philippe, additional, Montcuquet, Alexis, additional, Wahab, Abir, additional, Camdessanché, Jean-Philippe, additional, Marousset, Aude, additional, Patry, Ivania, additional, Hankiewicz, Karolina, additional, Pottier, Corinne, additional, Maubeuge, Nicolas, additional, Labeyrie, Céline, additional, Nifle, Chantal, additional, Leray, Emmanuelle, additional, Laplaud, David A, additional, Butzkueven, Helmut, additional, Kalincik, Tomas, additional, Vukusic, Sandra, additional, and Magyari, Melinda, additional

Published
2021
Full Text
View/download PDF

13. Artificial intelligence to predict clinical disability in patients with multiple sclerosis using FLAIR MRI

Author

Roca, P., primary, Attye, A., additional, Colas, L., additional, Tucholka, A., additional, Rubini, P., additional, Cackowski, S., additional, Ding, J., additional, Budzik, J.-F., additional, Renard, F., additional, Doyle, S., additional, Barbier, E.L., additional, Bousaid, I., additional, Casey, R., additional, Vukusic, S., additional, Lassau, N., additional, Verclytte, S., additional, Cotton, F., additional, Brochet, B., additional, De Sèze, J., additional, Douek, P., additional, Guillemin, F., additional, Laplaud, D., additional, Lebrun-Frenay, C., additional, Mansuy, L., additional, Moreau, T., additional, Olaiz, J., additional, Pelletier, J., additional, Rigaud-Bully, C., additional, Stankoff, B., additional, Marignier, R., additional, Debouverie, M., additional, Edan, G., additional, Ciron, J., additional, Ruet, A., additional, Collongues, N., additional, Lubetzki, C., additional, Vermersch, P., additional, Labauge, P., additional, Defer, G., additional, Cohen, M., additional, Fromont, A., additional, Wiertlewsky, S., additional, Berger, E., additional, Clavelou, P., additional, Audoin, B., additional, Giannesini, C., additional, Gout, O., additional, Thouvenot, E., additional, Heinzlef, O., additional, Al-Khedr, A., additional, Bourre, B., additional, Casez, O., additional, Cabre, P., additional, Montcuquet, A., additional, Créange, A., additional, Camdessanché, J.-P., additional, Faure, J., additional, Maurousset, A., additional, Patry, I., additional, Hankiewicz, K., additional, Pottier, C., additional, Maubeuge, N., additional, Labeyrie, C., additional, Nifle, C., additional, Ameli, R., additional, Anxionnat, R., additional, Bannier, E., additional, Barillot, C., additional, Ben Salem, D., additional, Boncoeur-Martel, M.-P., additional, Bonneville, F., additional, Boutet, C., additional, Brisset, J.-C., additional, Cervenanski, F., additional, Claise, B., additional, Commowick, O., additional, Constans, J.-M., additional, Dardel, P., additional, Desal, H., additional, Dousset, Vincent, additional, Durand-Dubief, F., additional, Ferre, J.-C., additional, Gerardin, E., additional, Glattard, T., additional, Grand, S., additional, Grenier, T., additional, Guillevin, R., additional, Guttmann, C., additional, Krainik, A., additional, Kremer, S., additional, Lion, S., additional, Menjot de Champfleur, N., additional, Mondot, L., additional, Outteryck, O., additional, Pyatigorskaya, N., additional, Pruvo, J.-P., additional, Rabaste, S., additional, Ranjeva, J.-P., additional, Roch, J.-A., additional, Sadik, J.C., additional, Sappey-Marinier, D., additional, Savatovsky, J., additional, Tanguy, J.-Y., additional, Tourbah, A., additional, and Tourdias, T., additional

Published
2020
Full Text
View/download PDF

14. New OFSEP recommendations for MRI assessment of multiple sclerosis patients: Special consideration for gadolinium deposition and frequent acquisitions

Author

Brisset, Jean-Christophe, primary, Kremer, Stephane, additional, Hannoun, Salem, additional, Bonneville, Fabrice, additional, Durand-Dubief, Francoise, additional, Tourdias, Thomas, additional, Barillot, Christian, additional, Guttmann, Charles, additional, Vukusic, Sandra, additional, Dousset, Vincent, additional, Cotton, Francois, additional, Ameli, R., additional, Anxionnat, R., additional, Audoin, B., additional, Attye, A., additional, Bannier, E., additional, Barillot, C., additional, Ben Salem, D., additional, Boncoeur-Martel, M.-P., additional, Bonhomme, G., additional, Bonneville, F., additional, Boutet, C., additional, Brisset, J.C., additional, Cervenanski, F., additional, Claise, B., additional, Commowick, O., additional, Constans, J.-M., additional, Cotton, F., additional, Dardel, P., additional, Desal, H., additional, Dousset, V., additional, Durand-Dubief, F., additional, Ferre, J.-C., additional, Gaultier, A., additional, Gerardin, E., additional, Glattard, T., additional, Grand, S., additional, Grenier, T., additional, Guillevin, R., additional, Guttmann, C., additional, Krainik, A., additional, Kremer, S., additional, Lion, S., additional, Champfleur, N. Menjot De, additional, Mondot, L., additional, Outteryck, O., additional, Pyatigorskaya, N., additional, Pruvo, J.-P., additional, Rabaste, S., additional, Ranjeva, J.-P., additional, Roch, J.-A., additional, Sadik, J.-C., additional, Sappey-Marinier, D., additional, Savatovsky, J., additional, Stankoff, B., additional, Tanguy, J.-Y., additional, Tourbah, A., additional, Tourdias, T., additional, Brochet, B., additional, Casey, R., additional, De Sèze, J., additional, Douek, P., additional, Guillemin, F., additional, Laplaud, D., additional, Lebrun-Frenay, C., additional, Mansuy, L., additional, Moreau, T., additional, Olaiz, J., additional, Pelletier, J., additional, Rigaud-Bully, C., additional, Vukusic, S., additional, Debouverie, M., additional, Edan, G., additional, Ciron, J., additional, Lubetzki, C., additional, Vermersch, P., additional, Labauge, P., additional, Defer, G., additional, Berger, E., additional, Clavelou, P., additional, Gout, O., additional, Thouvenot, E., additional, Heinzlef, O., additional, Al-Khedr, A., additional, Bourre, B., additional, Casez, O., additional, Cabre, P., additional, Montcuquet, A., additional, Créange, A., additional, Camdessanché, J.-P., additional, Bakchine, S., additional, Maurousset, A., additional, Patry, I., additional, De Broucker, T., additional, Pottier, C., additional, Neau, J.-P., additional, Labeyrie, C., additional, and Nifle, C., additional

Published
2020
Full Text
View/download PDF

15. État des lieux des patients de 55 ans et plus suivis pour une sclérose en plaques au CHU de Limoges

Author

Laurent Magy, Teddy Delpy, and Alexis Montcuquet

Subjects
Neurology, Neurology (clinical)
Abstract

Introduction Les progres de la medecine ont conduit a un vieillissement de la population de patients suivie pour une sclerose en plaques. L’analyse de leur prise en charge apparait necessaire. Objectifs Faire un etat des lieux des patients de 55 ans ou plus suivis pour une sclerose en plaques puis comparer leurs profils et evolutions cliniques selon la strategie therapeutique adoptee. Patients et methodes Etude monocentrique, retrospective, menee au CHU de Limoges. Les patients, issus de l’European Database for Multiple Sclerosis, devaient avoir 55 ans ou plus. Les donnees recueillies etaient : âge, Expanded Disability Status Scale (EDSS), sexe, duree de maladie, phenotype, traitement, nombre de poussees dans les 5 ans precedents le dernier suivi. Nous avons ensuite realise 3 groupes (patients traites, patients ayant arrete le traitement et patient n’ayant jamais eu de traitement) pour comparer leur evolution. Resultats Au total, 203 patients ont ete inclus. L’âge moyen est de 63,7 ans [55–86], avec un EDSS median de 5,5. Nous retrouvons 40 % de forme remittente-recurrente et autant de forme secondairement progressive. Sur les 203 patients, 54 n’ont jamais eu de traitement, 60 l’ont arrete et 89 en ont toujours un. Les 3 groupes sont comparables concernant l’activite de la maladie (taux annualise de poussees : 0,06) et l’EDSS lorsque le traitement a ete arrete apres 55 ans. Discussion Concernant cette population, plus de 50 % reste relativement autonome. Quarante-quatre pour cent ont encore un traitement de fond malgre les risques d’effets indesirables et leur cout economique. En accord avec les donnees de la litterature, l’evolution clinique des patients ayant stoppe le traitement apres 55 ans apparait rassurante. Conclusion Une part importante de patients ≥ 55 ans suivis pour une sclerose en plaques conservent une autonomie. Cette evolution justifie une adaptation des prises en charge et des strategies therapeutiques.

Published
2021
Full Text
View/download PDF

16. Syndrome paranéoplasique secondaire à une tumeur germinale testiculaire associée aux anticorps anti-KLHL11

Author

Laurent Magy, Anne Guyot, Abetare Krasniqi, Nathalie Deschamps, and Alexis Montcuquet

Subjects
Neurology, Neurology (clinical)
Abstract

Introduction La connaissance sur les syndromes neurologiques paraneoplasiques est en perpetuelle evolution. Certains symptomes comme le syndrome cerebelleux d’apparition subaigue doivent orienter fortement vers ce cadre nosologique. Observation Un homme de 55 ans presente une instabilite a la marche evoluant depuis 2 mois. A l’examen clinique il est retrouve un syndrome cerebelleux statique et cinetique predominant aux membres inferieurs. L’IRM cerebrale est normale. Le bilan biologique fait dans notre centre avec notamment les anticorps anti-Yo, anti-HU et anti-GAD est sans anomalie. Le TDM TAP est sans particularite. La PL met en evidence une meningite (29 elements/mm3) lymphocytaire sans cause infectieuse retrouvee. Dans l’hypothese d’une cause immune et possiblement paraneoplasique le patient beneficie d’une cure d’IgIV puis de boli de solumedrol sans franche amelioration. Le PET scan retrouve un ganglion sous diaphragmatique gauche qui a ete biopsie et decrit comme reactionnel initialement. Finalement, un anticorps anti-KLHL11 est retrouve dans le LCR confirmant l’origine paraneoplasique. L’echographie testiculaire retrouve un testicule gauche avec de multiples microcalcifications, hypotrophique et la relecture de la biopsie ganglionnaire avec des marquages specifiques est en faveur d’une tumeur germinale. Le patient beneficie d’une orchidectomie, et est oriente vers le service d’oncologie pour la suite de la prise en charge (chimiotherapie). Discussion Les anticorps anti-KLHL-11 de decouverte recente (2019) et jusqu’ici assez peu decrits, peuvent etre responsable de syndrome neurologique paraneoplasique avec notamment un syndrome cerebelleux et sont souvent associes aux tumeurs germinales testiculaire. Ces tumeurs peuvent se presenter sous forme de « burned-out tumor » : metastases de tumeur germinales avec regression (liee a une auto-immunite ou ischemie) de la tumeur primitive testiculaire. Conclusion Une ataxie cerebelleuse subaigue doit faire evoquer un syndrome paraneoplasique. Les connaissances actuelles avec les Ac anti-KLHL11 doivent faire rechercher notamment une origine testiculaire en attendant le resultat des anticorps.

Published
2021
Full Text
View/download PDF

17. Prévalence et prise en charge de la douleur chez les patients présentant un cancer métastatique en Franche-Comté

Author

Clotilde Verlut, Xavier Pivot, Nathalie Meneveau, Guillaume Mouillet, Marie Kroemer, Erion Dobi, Virginie Nerich, Philippe Montcuquet, Loic Chaigneau, Laurent Cals, Elsa Curtit, Thierry Nguyen Tan Hon, Mathieu Caubet, Fanny Dénommé, Marie-Justine Paillard, Laura Mansi, Tristan Maurina, Ulrich Stein, Hamadi Almotlak, Gilles Nallet, Martin Demarchi, Fernando Bazan, Antoine Thiery-Vuillemin, Héloïse Pana-Katatali, Cristian Villanueva, and Samuel Limat

Subjects
Gynecology, Cancer Research, medicine.medical_specialty, business.industry, Medication adherence, Hematology, General Medicine, Pain management, 03 medical and health sciences, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, medicine, Radiology, Nuclear Medicine and imaging, Self report, business, 030217 neurology & neurosurgery
Abstract

Resume Introduction La prise en charge de la douleur est un enjeu de sante publique important, particulierement en cancerologie. Dans une demarche d’evaluation des pratiques professionnelles, l’IRFC-FC a realise une enquete chez des patients presentant une tumeur solide metastatique osteophile en Franche-Comte. Les objectifs etaient d’evaluer la prevalence de la douleur, ses caracteristiques, sa prise en charge et son impact sur la qualite de vie. Methode Une enquete observationnelle, prospective et multicentrique a ete realisee via un questionnaire d’autoevaluation. Ont ete inclus les patients presentant un cancer metastatique du sein ou de la prostate pris en charge dans 5 hopitaux de jour de l’IRFC-FC sur une periode de 3 mois. Resultats Deux cent trente-trois questionnaires ont ete analyses. La prevalence de la douleur etait de 48,5 %. Trois-quarts des patients algiques avaient une douleur chronique de fond, d’intensite moderee a severe, associee ou non a des acces douloureux. Eu egard a l’intensite de leur douleur et a leur traitement antalgique, 42,0 % des patients semblaient sous-traites. Quatre-vingt-cinq pour cent des patients traites declaraient etre observants et estimaient que leur douleur etait bien prise en charge malgre un impact negatif sur la qualite de vie. Conclusion La mise en œuvre d’un chemin clinique est essentielle pour garantir une prise en charge standardisee, optimale et efficiente des patients algiques. L’evaluation de la satisfaction des soins et de la qualite de vie doit etre integree a la pratique clinique pour mieux identifier les patients algiques dont le traitement est inadapte.

Published
2016
Full Text
View/download PDF

19. Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society

Author

Lebrun, C., primary, Vukusic, S., additional, Abadie, V., additional, Achour, C., additional, Ader, F., additional, Alchaar, H., additional, Alkhedr, A., additional, Andreux, F., additional, Androdias, G., additional, Arjmand, R., additional, Audoin, B., additional, Audry, D., additional, Aufauvre, D., additional, Autreaux, C., additional, Ayrignac, X., additional, Bailbe, M., additional, Benazet, M., additional, Bensa, C., additional, Bensmail, D., additional, Berger, E., additional, Bernady, P., additional, Bertagna, Y., additional, Biotti, D., additional, Blanchard-Dauphin, A., additional, Bonenfant, J., additional, Bonnan, M., additional, Bonnemain, B., additional, Borgel, F., additional, Botelho-Nevers, E., additional, Boucly, S., additional, Bourre, B., additional, Boutière, C., additional, Branger, P., additional, Brassat, D., additional, Bresch, S., additional, Breuil, V., additional, Brochet, B., additional, Brugeilles, H., additional, Bugnon, P., additional, Cabre, P., additional, Camdessanché, J.-P., additional, Carra-Dalière, C., additional, Casez, O., additional, Chamouard, J.-M., additional, Chassande, B., additional, Chataignier, P., additional, Chbicheb, M., additional, Chenet, A., additional, Ciron, J., additional, Clavelou, P., additional, Cohen, M., additional, Colamarino, R., additional, Collongues, N., additional, Coman, I., additional, Corail, P.-R., additional, Courtois, S., additional, Coustans, M., additional, Creange, A., additional, Creisson, E., additional, Daluzeau, N., additional, Davenas, C., additional, De Seze, J., additional, Debouverie, M., additional, Depaz, R., additional, Derache, N., additional, Divio, L., additional, Douay, X., additional, Dulau, C., additional, Durand-Dubief, F., additional, Edan, G., additional, Elias, Z., additional, Fagniez, O., additional, Faucher, M., additional, Faucheux, J.-M., additional, Fournier, M., additional, Gagneux-Brunon, A., additional, Gaida, P., additional, Galli, P., additional, Gallien, P., additional, Gaudelus, J., additional, Gault, D., additional, Gayou, A., additional, Genevray, M., additional, Gentil, A., additional, Gere, J., additional, Gignoux, L., additional, Giroux, M., additional, Givron, P., additional, Gout, O., additional, Grimaud, J., additional, Guennoc, A.-M., additional, Hadhoum, N., additional, Hautecoeur, P., additional, Heinzlef, O., additional, Jaeger, M., additional, Jeannin, S., additional, Kremer, L., additional, Kwiatkowski, A., additional, Labauge, P., additional, Labeyrie, C., additional, Lachaud, S., additional, Laffont, I., additional, Lanctin-Garcia, C., additional, Lannoy, J., additional, Lanotte, L., additional, Laplaud, D., additional, Latombe, D., additional, Lauxerois, M., additional, Le Page, E., additional, Lebrun-Frenay, C., additional, Lejeune, P., additional, Lejoyeux, P., additional, Lemonnier, B., additional, Leray, E., additional, Loche, C.-M., additional, Louapre, C., additional, Lubetzki, C., additional, Maarouf, A., additional, Mada, B., additional, Magy, L., additional, Maillart, E., additional, Manchon, E., additional, Marignier, R., additional, Marque, P., additional, Mathey, G., additional, Maurousset, A., additional, Mekies, C., additional, Merienne, M., additional, Michel, L., additional, Milor, A.-M., additional, Moisset, X., additional, Montcuquet, A., additional, Moreau, T., additional, Morel, N., additional, Moussa, M., additional, Naudillon, J.-P., additional, Normand, M., additional, Olive, P., additional, Ouallet, J.-C., additional, Outteryck, O., additional, Pacault, C., additional, Papeix, C., additional, Patry, I., additional, Peaureaux, D., additional, Pelletier, J., additional, Pichon, B., additional, Pittion, S., additional, Planque, E., additional, Pouget, M.-C., additional, Pourcher, V., additional, Radot, C., additional, Robert, I., additional, Rocher, F., additional, Ruet, A., additional, Saint-Val, C., additional, Salle, J.-Y., additional, Salmon, A., additional, Sartori, E., additional, Schaeffer, S., additional, Stankhof, B., additional, Taithe, F., additional, Thouvenot, E., additional, Tizon, C., additional, Tourbah, A., additional, Tourniaire, P., additional, Vaillant, M., additional, Vermersch, P., additional, Vidil, S., additional, Wahab, A., additional, Warter, M.-H., additional, Wiertlewski, S., additional, Wiplosz, B., additional, Wittwer, B., additional, Zaenker, C., additional, and Zephir, H., additional

Published
2019
Full Text
View/download PDF

20. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Author

Pivot, Xavier, primary, Romieu, Gilles, additional, Debled, Marc, additional, Pierga, Jean-Yves, additional, Kerbrat, Pierre, additional, Bachelot, Thomas, additional, Lortholary, Alain, additional, Espié, Marc, additional, Fumoleau, Pierre, additional, Serin, Daniel, additional, Jacquin, Jean-Philippe, additional, Jouannaud, Christelle, additional, Rios, Maria, additional, Abadie-Lacourtoisie, Sophie, additional, Venat-Bouvet, Laurence, additional, Cany, Laurent, additional, Catala, Stéphanie, additional, Khayat, David, additional, Gambotti, Laetitia, additional, Pauporté, Iris, additional, Faure-Mercier, Celine, additional, Paget-Bailly, Sophie, additional, Henriques, Julie, additional, Grouin, Jean Marie, additional, Piprot, C, additional, Cals, L, additional, Chaigneau, L, additional, Demarchi, F, additional, N'Guyen, T, additional, Stein, U, additional, Villanueva, C, additional, Bréau, JL, additional, Chouahnia, AK, additional, Saintigny, P, additional, Boué, F, additional, deSaint-Hilaire, P, additional, Guimont, I, additional, Grossat, N, additional, Valenza, B, additional, Lévy, E, additional, Médioni, J, additional, Delbaldo, C, additional, Grenier, J, additional, Pouessel, D, additional, Lavau-Denès, S, additional, Falandry, C, additional, Fournel-Fédérico, C, additional, Freyer, G, additional, Tartas, S, additional, Trillet-Lenoir, V, additional, Bons, F, additional, Auclerc, G, additional, Chièze, S, additional, Raban, N, additional, Tournigand, C, additional, Trager-Maury, S, additional, Bousquet, G, additional, Cuvier, C, additional, Giacchetti, S, additional, Hocini, A, additional, LeMaignan, C, additional, Misset, JL, additional, Avenin, D, additional, Beerblock, C, additional, Gligorov, J, additional, Rivera, P, additional, Roché, H, additional, Bougnoux, P, additional, Hajjaji, N, additional, Capitain, O, additional, Delva, R, additional, Maillart, P, additional, Soulié, P, additional, Bonnefoi, H, additional, Durand, M, additional, Madranges, N, additional, Mauriac, L, additional, Chollet, P, additional, Dillies, AF, additional, Durando, X, additional, Ferrière, JP, additional, Mouret-Reynier, C, additional, Nabholtz, JM, additional, Van Praagh, I, additional, Cottu, P, additional, Diéras, V, additional, Durieux, A, additional, Galotte, M, additional, Girre, V, additional, Henry, S, additional, Iurisci, I, additional, Jouve, M, additional, Laurence, V, additional, Mignot, L, additional, Piperno-Neumann, S, additional, Tresca, P, additional, Coudert, B, additional, Ferrant, E, additional, Mayer, F, additional, Vanneuville, AC, additional, Bonneterre, J, additional, Servent, V, additional, Vanlemmens, L, additional, Vennin, P, additional, Guastalla, JP, additional, Biron, P, additional, Dupuy-Brousseau, L, additional, Lancry, L, additional, Ray-Coquard, I, additional, Rebattu, P, additional, Trédan, O, additional, Extra, JM, additional, Rousseau, F, additional, Tarpin, C, additional, Fabbro, M, additional, Luporsi, E, additional, Uwer, L, additional, Weber, B, additional, Berton-Rigaud, D, additional, Bourbouloux, E, additional, Campone, M, additional, Ferrero, JM, additional, Follana, P, additional, Largillier, R, additional, Mari, V, additional, Costa, B, additional, Curé, H, additional, Eymard, JC, additional, Jovenin, N, additional, Lebrun, D, additional, Meunier, J, additional, Yazbek, G, additional, Gedoin, D, additional, Laguerre, B, additional, Lefeuvre, C, additional, Vauléon, E, additional, Chevrier, A, additional, Guillemet, C, additional, Leheurteur, M, additional, Rigal, O, additional, Tennevet, I, additional, Veyret, C, additional, Brain, E, additional, Guiterrez, M, additional, Mefti-Lacheraf, F, additional, Petit, T, additional, Dalenc, F, additional, Gladieff, L, additional, André, F, additional, Delaloge, S, additional, Domont, J, additional, Ezenfis, J, additional, Spielmann, M, additional, Guillet, P, additional, Boulanger, V, additional, Provençal, J, additional, Stefani, L, additional, Alliot, C, additional, Ré, D, additional, Bellaiche-Miccio, C, additional, Boutan-Laroze, G, additional, Vanica, R, additional, Dion, P, additional, Sadki-Benaoudia, G, additional, Marti, A, additional, Villing, AL, additional, Slama, B, additional, Dutel, JL, additional, Nguyen, S, additional, Saad, R, additional, Arsène, O, additional, Merad-Boudia, Z, additional, Orfeuvre, H, additional, Egreteau, J, additional, Goudier, MJ, additional, Lamy, R, additional, Leduc, B, additional, Sarda, C, additional, Salles, B, additional, Agostini, C, additional, Cauvin, I, additional, Dufresne, A, additional, Mangold, M, additional, Lebouvier-Sadot, S, additional, Audhuy, B, additional, Barats, JC, additional, Cluet-Dennetière, S, additional, Zylberait, D, additional, Netter, G, additional, Gautier-Felizot, L, additional, Cojean-Zelek, I, additional, Plantade, A, additional, Vignot, S, additional, Guardiola, E, additional, Marti, P, additional, deHartingh, I, additional, Diab, R, additional, Dietmann, A, additional, Ruck, S, additional, Portois, C, additional, Oddou-Lagranière, S, additional, Campos-Gazeau, F, additional, Bourcier, A, additional, Priou, F, additional, Geay, JF, additional, Mayeur, D, additional, Gabez, P, additional, ElAmarti, R, additional, Combe, M, additional, Raichon-Patru, P, additional, Amsalhem, P, additional, Dauba, J, additional, Paraiso, D, additional, Guinet, F, additional, Duvert, B, additional, Litor, M, additional, Kara-Slimane, F, additional, Bichoffe, A, additional, Denizon, N, additional, Soyer, P, additional, Morvan, F, additional, Van-Hulst, S, additional, Vincent, L, additional, Alleaume, C, additional, Ibanez-Martin, P, additional, Youssef, A, additional, Tadrist, Z, additional, Carola, E, additional, Pourny, C, additional, Toccanier, JF, additional, Al-Aukla, N, additional, Mahour-Bacha, K, additional, Salvat, J, additional, Nouyrigat, P, additional, Clippe, S, additional, Gouttebel, MC, additional, Vedrine, L, additional, Clavreul, G, additional, Collard, O, additional, Mille, D, additional, Goubely, Y, additional, Hervé, R, additional, Kirscher, S, additional, Plat, F, additional, Delecroix, V, additional, Ligeza-Poisson, V, additional, Coeffic, D, additional, Fric, D, additional, Garnier, C, additional, Leyronnas, C, additional, Kreitman, T, additional, Teissier, E, additional, Martin, P, additional, Rohart deCordoue, S, additional, ElKouri, C, additional, Ramée, JF, additional, Laporte, C, additional, Bernard, O, additional, Altwegg, T, additional, Darut-Jouve, A, additional, Dujols, JP, additional, Darloy, F, additional, Giraud, C, additional, Pottier-Kyndt, V, additional, Achour, N, additional, Drony, S, additional, Moriceau, M, additional, Sarrazin, C, additional, Legueul, JC, additional, Mandet, J, additional, Besson, D, additional, Hardy-Bessard, AC, additional, Cretin, J, additional, Houyau, P, additional, Achille, E, additional, Genêt, D, additional, Thévenot, H, additional, Moran-Ribon, A, additional, Pavlovitch, JM, additional, Ardisson, P, additional, Moullet, I, additional, Couderc, B, additional, Fichet, V, additional, Burki, F, additional, Auliard, A, additional, Levaché, CB, additional, Cailleux, P, additional, Schaeffer, F, additional, Albin, N, additional, Sévin-Robiche, D, additional, Domas, J, additional, Ellis, S, additional, Montcuquet, P, additional, Baumont, GA, additional, Bégue, M, additional, Gréget, S, additional, Ratoanina, JL, additional, Vanoli, A, additional, Bielsa, C, additional, Bonichon-Lamichhane, M, additional, Jaubert, D, additional, Laharie-Mineur, H, additional, Alcaraz, L, additional, Legouffe, E, additional, Bourgeois, H, additional, Cartron, G, additional, Denis, F, additional, Dupuis, O, additional, Ganem, G, additional, Roche-Forestier, S, additional, Delzenne, L, additional, Chirat, E, additional, Baticle, JL, additional, Béguier, E, additional, Jacquot, S, additional, Janssen, E, additional, Lauché, H, additional, LeRol, A, additional, Chantelard, JP, additional, L'Helgoualc'h, GA, additional, Antoine, EC, additional, Kanoui, A, additional, Llory, JF, additional, Vannetzel, JM, additional, Vignoud, J, additional, Bruna, C, additional, Facchini, T, additional, Moutel-Corviole, K, additional, Voloch, A, additional, Ghoul, A, additional, Loiseau, D, additional, Barbet, N, additional, Dohollou, N, additional, and Yakendji, K, additional

Published
2019
Full Text
View/download PDF

21. Efficacité, tolérance et coût de l’éribuline chez des patientes présentant un cancer du sein métastatique

Author

Philippe Montcuquet, Marie-Justine Paillard, Fernando Bazan, Xavier Pivot, Cristian Villanueva, Laura Mansi, Elsa Curtit, Antoine Thiery-Vuillemin, Erion Dobi, Nathalie Meneveau, Loic Chaigneau, and Virginie Nerich

Subjects
Cancer Research, Oncology, Radiology, Nuclear Medicine and imaging, Hematology, General Medicine
Abstract

Resume L’eribuline a obtenu son autorisation de mise sur le marche (AMM) en mars 2011 pour le traitement des patientes atteintes de cancer du sein localement avance ou metastatique ayant progresse apres anthracycline et taxane. L’objectif de cette etude etait d’evaluer retrospectivement l’efficacite, la tolerance et le cout de ce traitement chez les patientes traitees en Franche-Comte pour un cancer du sein metastatique (CSM) ayant recu l’eribuline. Quatre-vingt-dix patientes ont ete traitees par eribuline entre juillet 2006 et octobre 2013. L’âge median etait de 62 ans (35–83). La survie globale etait de 10,3 mois [IC 95 % : 7,6–17,9], la survie sans progression mediane de 3,8 mois [IC 95 % : 2,9–5,0]. Un benefice clinique a ete obtenu chez 55 % des patientes [IC 95 % : 43,1–66,9] evaluable selon les criteres RECIST. Les effets indesirables de grade 3 et 4 les plus frequents etaient la neutropenie (38 %), l’asthenie (10 %) et la neuropathie peripherique (7 %). Le cout median du traitement etait de 9767 € par patiente (6344–17 517). Cette analyse a retrouve des resultats comparables a l’etude EMBRACE malgre une population moins selectionnee. Une evaluation medico-economique de type cout–utilite permettrait d’evaluer l’efficacite de cette strategie therapeutique comparativement aux traitements standard.

Published
2015
Full Text
View/download PDF

22. Évaluation économique de l’utilisation en routine du test Oncotype DX® dans la prise en charge des cancers du sein en Franche-Comté

Author

Hamadi Altmotlak, Gilles Nallet, Philippe Montcuquet, Erion Dobi, Xavier Pivot, Marie-Jeanne Choulot, Loic Chaigneau, Cristian Villanueva, Virginie Nerich, Fernando Bazan, Laurent Cals, Elsa Curtit, Marie-Paule Algros, Sylvie Mansion, Samuel Limat, and Nathalie Meneveau

Subjects
Cancer Research, Oncology, Radiology, Nuclear Medicine and imaging, Hematology, General Medicine
Abstract

Resume La signature genomique Oncotype DX ® est capable d’estimer le risque de recidive et de predire le benefice potentiel d’une chimiotherapie adjuvante pour un cancer du sein localise RE+ et HER-2 negatif. En 2012, grâce a l’Agence Regionale de Sante de Franche-Comte, ce test a ete disponible en routine dans la region. Les patientes pouvant en beneficier devaient presenter un cancer du sein localise RE+, HER-2-, avec un envahissement ganglionnaire absent ou limite a un ganglion sans rupture capsulaire et etre candidates a une chimiotherapie adjuvante sur les criteres histopathologiques et/ou cliniques classiques. En situation de limitations des ressources et de contraintes budgetaires, l’objectif de cette etude est d’evaluer l’impact economique de l’utilisation du test Oncotype DX ® en Franche-Comte. Pour y repondre, une evaluation de type minimisation de cout a ete realisee. Propose a 48 patientes, le test Oncotype DX ® a permis d’eviter une chimiotherapie adjuvante dans 73 % des cas. Cela se traduit par une absence de surcout lie a sa realisation, voire une economie potentielle pour l’Assurance-Maladie. Devant le succes de cette strategie pilote, la generalisation de l’utilisation du test Oncotype DX ® sur l’ensemble du territoire sous reserve d’une organisation stricte est a considerer rapidement par les autorites de sante.

Published
2014
Full Text
View/download PDF

23. Traitements néoadjuvants préopératoires : mise au point dans le cancer de la prostate

Author

L. Martin, G. Guichard, P. Montcuquet, G. Mouillet, V. Richard, M.-J. Paillard, N. Lescut, Antoine Thiery-Vuillemin, François Kleinclauss, and T. Maurina

Subjects
Gynecology, medicine.medical_specialty, business.industry, Urology, medicine, business
Abstract

Resume But Evaluer l’apport d’un traitement systemique en situation neoadjuvante dans le cancer de la prostate avant prostatectomie Materiels Revue de la litterature avec analyse des donnees tirees de recherche sur Pubmed a l’aide des mots cles neoadjuvant , chemotherapy , hormonal therapy , prostate surgery , radical prostatectomy , mais aussi de rapport de congres comme l’ASCO et ESMO. Les articles concernant sur les traitements neoadjuvants avant radiotherapie etaient exclus. Resultats Les premieres etudes sont anciennes avec une methodologie le plus souvent critiquable : manque de puissance pour avoir une idee precise de l’impact sur des criteres de survie a plus long terme de type survie globale ou survie sans rechute. Neanmoins, l’impact de l’hormonotherapie neoadjuvante sur les facteurs de risques de rechutes classiques (marges operatoire, maladie intraprostatique, atteinte ganglionnaire) a ete demontre par ces etudes et une meta-analyse de la Cochrane. L’association avec une hormonotherapie semble necessaire par rapport a un traitement reposant uniquement sur chimiotherapie et/ou therapie ciblee. Quelques donnees emergent sur l’utilisation des nouvelles molecules et leur combinaisons : l’acetate d’abiraterone a montre en association avec un analogue de LHRH une baisse du PSA plus rapide et des taux de reponse complete histologique plus importants. D’autres resultats sont prometteurs avec blocages hormonaux aux divers points cles. Conclusion Les etudes avec les hormonotherapies de type anti-androgenes de 2 e generation ou inhibiteurs enzymatiques semblent montrer des resultats tres prometteurs. Afin d’apporter des reponses sur l’efficacite d’une strategie neoadjuvante actuelle du point de vue de la survie, d’autres etudes de phase III randomises ou de phase II avec recherche de biomarqueurs predictifs sont necessaires. La conception de tels essais necessite une vision multidisciplinaire avec urologues, oncologues, radiologues et methodologistes.

Published
2014
Full Text
View/download PDF

24. Long-term follow-up of patients with metastatic breast cancer treated by trastuzumab: Impact of institutions

Author

Philippe Montcuquet, Cristian Villanueva, Sophie Perrin, Laurent Cals, Erion Dobi, Samuel Limat, Virginie Nerich, Nathalie Meneveau, Xavier Pivot, Loic Chaigneau, Frédéric Fiteni, and Fernando Bazan

Subjects
Oncology, medicine.medical_specialty, Multivariate analysis, Long term follow up, medicine.medical_treatment, Antineoplastic Agents, Breast Neoplasms, Antibodies, Monoclonal, Humanized, Breast cancer, Trastuzumab, Internal medicine, medicine, Humans, Neoplasm Metastasis, skin and connective tissue diseases, neoplasms, Aged, Proportional Hazards Models, Chemotherapy, Univariate analysis, business.industry, General Medicine, Middle Aged, Prognosis, medicine.disease, Survival Analysis, Metastatic breast cancer, Clinical trial, Treatment Outcome, Female, Surgery, business, Follow-Up Studies, medicine.drug
Abstract

Trastuzumab in Human Epidermal growth Receptor 2-positive (HER2+) metastatic breast cancer (MBC) was established as standard therapy since 2001. The objective of this study was to search for significant prognostic factors in patients with HER2+ MBC treated by trastuzumab taking into account the institution where the treatment was given.All patients with HER2+ MBC treated by trastuzumab between 2001 and 2010 in the 8 hospitals of Franche Comte region were analysed. Univariate and multivariate analysis were conducted to search for factors related to overall survival (OS).Among 1234 patients with MBC treated by chemotherapy between 2001 and 2010, 217 patients received trastuzumab. In this subset, the median age was 60 years, 8% and 38% had brain and liver metastases at first occurrence of MBC, 36% of, tumours were hormonal receptors positive. Patients were treated in 48% and 52% of cases in specialized and in general hospitals, respectively. The median OS length was 45.2 months (IQR 23.2-89.3 months). In univariate analysis the following factors were significantly related to favourable OS: inclusion in clinical trials, treatment in a specialized hospital, positive hormonal receptors status, age50. In multivariate analysis remained significant: treatment in specialized hospital (aHR 0.78; 95%CI 0.64-0.94; p = 0.03) and age50 (aHR 0.76; 95%CI 0.59-0.95; p = 0.02).Exposure to trastuzumab erases all established prognostic factors at the metastatic setting. The fact that patients treated in specialized hospitals presented a longer survival emphasizes the dramatic impact of this therapy and the relevance to optimize its use.

Published
2014
Full Text
View/download PDF

25. Interleukin 15 and CD4+ T Cells Cooperate to Promote Small Intestinal Enteropathy in Response to Dietary Antigen

Author

Nicolas Montcuquet, Nadine Cerf-Bensussan, Emma Ramiro-Puig, Hiroshi Kiyono, Julie Schulthess, Natalia Korneychuk, Bertrand Meresse, and Julien Ettersperger

Subjects
CD4-Positive T-Lymphocytes, Ovalbumin, Regulatory T cell, CD8-Positive T-Lymphocytes, Biology, Lymphocyte Activation, T-Lymphocytes, Regulatory, Cell Degranulation, Granzymes, Mice, Interleukin 21, Antigen, Intestine, Small, medicine, Animals, Humans, Cytotoxic T cell, Enteropathy, IL-2 receptor, Antigens, Intestinal Mucosa, Immunity, Mucosal, Cells, Cultured, Cell Proliferation, Interleukin 3, Interleukin-15, Mice, Knockout, Hepatology, Histocompatibility Antigens Class II, Gastroenterology, Dendritic cell, medicine.disease, Adoptive Transfer, Coculture Techniques, Diet, DNA-Binding Proteins, Mice, Inbred C57BL, Celiac Disease, Disease Models, Animal, Phenotype, medicine.anatomical_structure, Immunology, Cytokines, Interleukin-2, beta 2-Microglobulin, Spleen, Signal Transduction
Abstract

Background & Aims CD4 + T cells specific for dietary gluten and interleukin 15 (IL15) contribute to the pathogenesis of celiac disease. We investigated whether and how they interact to damage the intestine using mice that overexpress human IL15 in the intestinal epithelium and have CD4 + T cells specific for ovalbumin, a dietary antigen. Methods We crossed mice with CD4 + T cells specific for ovalbumin (OTII) with mice that overexpress human IL15 under an intestine-specific promoter (B6 × IL15Tge). The offspring (OTII × IL15Tge mice) received control or ovalbumin-containing diets until 3 months of age. Enteropathy was monitored by weight, ratio of villous:crypt length, and the number of intestinal lymphocytes. Phenotype, cytokine production, and degranulation of mucosal and spleen lymphocytes were analyzed by multicolor flow cytometry or enzyme-linked immunosorbent assay. Regulatory T-cell function and CD8 + T-cell activation were analyzed in co-culture assays. Results Exposure to ovalbumin reduced growth and led to enteropathy in OTII × IL15Tge mice but not in control OTII × B6 littermates. Enteropathy was associated with expansion of mucosal granzyme B + CD8 + T cells, and developed despite increased frequency of functional ovalbumin-specific regulatory T cells. Ovalbumin-activated CD4 + T cells secreted IL2, which along with IL15 stimulated expansion of noncognate intestinal cytotoxic CD8 + T cells, which did not respond to regulatory T cells and induced epithelial damage. Conclusions We observed that in mice given food antigen, cooperation between IL15 and CD4 + T cells is necessary and sufficient to activate CD8 + T cells and damage the small intestine. We propose that this process is involved in the development of celiac disease.

Published
2014
Full Text
View/download PDF

26. Prolonged overall survival for patients with bone-only metastases at presentation of metastatic breast cancer

Author

Curtit, E., primary, Bazan, F., additional, Chaigneau, L., additional, Mouillet, G., additional, Dobi, E., additional, Mansi, L., additional, Meneveau, N., additional, Paillard, M.-J., additional, Meynard, G., additional, Klajer, E., additional, Villanueva, C., additional, Montcuquet, P., additional, Pivot, X., additional, and Cals, L., additional

Published
2018
Full Text
View/download PDF

27. Impact of BRCA status on outcomes and survival in high-risk early breast cancers

Author

Klajer, E., primary, Paget-Bailly, S., additional, Meynard, G., additional, Meurisse, A., additional, Bazan, F., additional, Chaigneau, L., additional, Dobi, E., additional, Meneveau, N., additional, Montcuquet, P., additional, Villanueva, C., additional, Thiery-Vuillemin, A., additional, Kalbacher, E., additional, Populaire, C., additional, Collonge-Rame, M.-A., additional, Gligorov, J., additional, Curtit, E., additional, Pivot, X., additional, and Mansi, L., additional

Published
2018
Full Text
View/download PDF

30. Interleukin-15-Dependent NKp46+ Innate Lymphoid Cells Control Intestinal Inflammation by Recruiting Inflammatory Monocytes

Author

Julie Schulthess, Christophe Combadière, Dominique Buzoni-Gatel, Nadine Cerf-Bensussan, Bernadette Bègue, Emma Ramiro-Puig, Bertrand Meresse, James P. Di Santo, Franck M. Ruemmele, Nicolas Montcuquet, Sylvie Darche, U989, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5), Université Paris Descartes - Paris 5 (UPD5), Institut Pasteur [Paris], Physiopathologie du Système Immunitaire, Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur [Paris], CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM), Université Pierre et Marie Curie - Paris 6 (UPMC), Infectiologie et Santé Publique (UMR ISP), Institut National de la Recherche Agronomique (INRA)-Université de Tours (UT), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Recherche Agronomique (INRA)-Université de Tours, ProdInra, Migration, Immunité Innée, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), and The authors acknowledge funding from INSERM, Fondation Pour la Recherche Médicale, Agence Nationale pour la Recherche (ANR), Association François Aupetit, and Fondation Princesse Grace. J.S. was supported by a MNERT PhD fellowship. E.R.-P. and N.M. were supported by postdoctoral fellowships from Fundacion Espanola para la Ciencia y Tecnologia (FECYT), Fundacion Pedro I Pons, and from FRM and ANR, respectively.

Subjects
Male, CCR1, Chemokine, Adolescent, [SDV.IMM] Life Sciences [q-bio]/Immunology, Immunology, Receptors, CCR1, CCL3, Monocytes, Interleukin-7 Receptor alpha Subunit, Mice, 03 medical and health sciences, Chemokine receptor, 0302 clinical medicine, Crohn Disease, parasitic diseases, medicine, Animals, Antigens, Ly, Humans, Immunology and Allergy, Ileitis, Lymphocytes, Intestinal Mucosa, Child, Chemokine CCL3, 030304 developmental biology, Interleukin-15, Mice, Knockout, 0303 health sciences, Lamina propria, biology, Natural Cytotoxicity Triggering Receptor 1, Innate lymphoid cell, Interleukin-18, Th1 Cells, medicine.disease, Enteritis, Mice, Inbred C57BL, medicine.anatomical_structure, Infectious Diseases, Interleukin 15, biology.protein, [SDV.IMM]Life Sciences [q-bio]/Immunology, Toxoplasma, NK Cell Lectin-Like Receptor Subfamily B, 030215 immunology
Abstract

International audience; With the goal in mind to define how interleukin-15 (IL-15) contributes to acute intestinal inflammation, we have used a mouse model of ileitis induced by oral infection with Toxoplasma gondii. We observed that a crosstalk between IL-15 and interleukin-18 (IL-18) promoted intestinal recruitment of inflammatory monocytes, where these cells participated in parasite control but also in tissue damage. A stromal source of IL-15 controlled the development of lamina propria NKp46(+)NK1.1(+) cells, whereas IL-18 produced during T. gondii infection stimulated their production of the chemokine CCL3. In turn, CCL3 attracted inflammatory monocytes via their chemokine receptor CCR1, which was indispensable for their recruitment into the inflamed gut. Collectively, these results identify the IL-15-dependent subset of intestinal NKp46(+) cells as an important source of CCL3, which can amplify intestinal inflammation via the recruitment of CCR1(+) inflammatory monocytes. Preliminary evidence suggests that this pathway might operate in Crohn's disease.

Published
2012
Full Text
View/download PDF

31. Cas de méningo-encéphalite à Trypanosomiase

Author

Laurent Magy, Jean-François Faucher, Anna Larricq, Morgan Matt, Marie Paule Boncoeur, and Alexis Montcuquet

Subjects
Gynecology, medicine.medical_specialty, Neurology, business.industry, medicine, Meningo encephalite, Neurology (clinical), business
Abstract

Introduction La Trypanosomiase humaine africaine est une parasitose endemique dans certaines regions d’Afrique subsaharienne. Elle peut etre responsable d’atteinte encephalitique severe pouvant aller jusqu’au deces si elle n’est pas prise en charge a temps. Observation Nous rapportons ici le cas d’une jeune patiente de 21 ans originaire du Congo, arrivee en France recemment. Celle-ci a presente rapidement des troubles du comportement, de l’humeur, du sommeil et un syndrome confusionnel, pour lesquels elle a consulte aux urgences a plusieurs reprises. Un syndrome infectieux est apparu par la suite. La ponction lombaire retrouvait dans le LCR 225 elements. l’IRM cerebral retrouvait des hypersignaux diffus de la substance blanche bilateral, en sequence FLAIR, sus et sous tentoriels. La serologie positive dans le LCR a permis de porter le diagnostic de meningoencephalite a Trypanosoma brucei. La patiente a beneficie d’un traitement anti-infectieux par Eflornithine et Nifurtimox. L’evolution clinique a 6 mois mettait en evidence des sequelles neuro psychologiques avec une labilite thymique, un syndrome dysexecutif, et des troubles phasiques. L’IRM cerebral de controle montrait une nette regression des hypersignaux de la substance blanche. Discussion La description des cas de meningoencephalites a Trypanosomiases et notamment la description des lesions cerebrales a l’IRM est assez rare dans la litterature. Un diagnostic est possible avec de simples serologies et des traitements antibiotiques efficaces existent a la phase cerebrale. Cependant la meconnaissance de cette pathologie peut aboutir a un retard diagnostic et a une issue fatale. Conclusion La trypanosomiase humaine africaine peut se rencontrer dans nos hopitaux par les migrants ou les voyageurs. Un diagnostic precoce de la phase cerebrale pourrait permettre de limiter les sequelles neurologiques.

Published
2017
Full Text
View/download PDF

32. Prolonged overall survival for patients with bone-only metastases at presentation of metastatic breast cancer

Author

Xavier Pivot, Fernando Bazan, G. Meynard, Philippe Montcuquet, Elsa Curtit, Guillaume Mouillet, N. Meneveau, Erion Dobi, M.-J. Paillard, Elodie Klajer, L. Cals, Loic Chaigneau, Cristian Villanueva, and Laura Mansi

Subjects
Oncology, medicine.medical_specialty, business.industry, Internal medicine, medicine, Overall survival, Hematology, Presentation (obstetrics), business, medicine.disease, Metastatic breast cancer
Published
2018
Full Text
View/download PDF

33. Impact of BRCA status on outcomes and survival in high-risk early breast cancers

Author

Laura Mansi, Cristian Villanueva, Sophie Paget-Bailly, Aurélia Meurisse, Philippe Montcuquet, Fernando Bazan, Xavier Pivot, Elsa Curtit, Elsa Kalbacher, C. Populaire, N. Meneveau, Elodie Klajer, Loic Chaigneau, Joseph Gligorov, M.-A. Collonge-Rame, G. Meynard, Antoine Thiery-Vuillemin, and Erion Dobi

Subjects
Oncology, medicine.medical_specialty, business.industry, Internal medicine, medicine, Hematology, business
Published
2018
Full Text
View/download PDF

34. IRIS du système nerveux central après allogreffe

Author

Solène Hebert, Pierre Clavel, Pascal Turlure, Laurent Magy, and Alexis Montcuquet

Subjects
Neurology, Neurology (clinical)
Abstract

Introduction Le syndrome inflammatoire de reconstitution immune est une complication grave rapportee chez les patients redevenus immunocompetants apres une phase d’immunodepression severe, en lien avec le VIH ou apres traitement immunosuppresseur. Observation Une patiente de 54 ans suivie initialement pour une LAM ; en remission pendant 14 ans ; a presente une rechute en 2015 traitee par chimiotherapie et allogreffe. Complication par GVH aigue controlee par corticotherapie courte et augmentation de la cyclosporine. Un an apres, elle presentait un tableau neurologique subaigu avec deficit sensitivomoteur du membre inferieur droit. La LAM etait alors en remission. L’IRM cerebrale retrouvait une lesion rehaussee d’allure inflammatoire parietale gauche. Le bilan etiologique ne retrouvait pas d’argument pour une pathologie chronique inflammatoire du SNC (pas de synthese intrathecale) ni maladie systemique ou tumorale. Elle fut traitee par corticotherapie courte a forte dose et recupera totalement. En mai 2016 elle representa les memes symptomes. L’IRM retrouvait de multiples lesions pseudo tumorales toujours d’allure inflammatoire avec rehaussement annulaire. La ponction lombaire restait normale. La biopsie cerebrale retrouvait un remaniement inflammatoire demyelinisant, sans argument pour une pathologie tumorale ou lymphomateuse. Apres corticotherapie forte elle recupera. Les lesions diminuait sur l’IRM a 2 mois. Devant cette rechute, un traitement par rituximab fut debute apres RCP. La patiente est stable depuis. Discussion Au vu de l’antecedent d’immunodepression et l’elimination des diagnostics differentiels, le diagnostic d’IRIS du systeme nerveux central a ete retenu. Cette reaction est rare mais a ete decrite, on y retrouve l’imputabilite de l’allogreffe et des corticoides (par leur diminution) qui conduisent a une reconstitution de l’immunite. Le rituximab a ete choisi dans une demarche prophylactique d’eventuelles autres poussees. Conclusion L’IRIS du SNC est une complication severe, a presentation variable pouvant apparaitre a distance d’une restauration immunitaire, elle doit etre evoquee chez tout patient ayant presente un etat d’immunodepression.

Published
2018
Full Text
View/download PDF

35. Pseudo-Guillain Barré, révélant un lymphome endovasculaire

Author

Alexis Montcuquet, Mathilde Duchesne, Sophie Lefour, and Laurent Magy

Subjects
Neurology, Neurology (clinical)
Abstract

Introduction Le lymphome endovasculaire est une hemopathie rare, difficile a diagnostiquer. S’il n’est pas rare de rencontrer des manifestations neurologiques centrales au cours de cette affection, les polyradiculonevrites sont peu decrites. Observation Nous rapportons le cas d’un patient de 48 ans, sans antecedent, qui a presente de facon soudaine des troubles de la marche associes a des troubles vesico-sphincteriens. Devant ce qui semblait etre un syndrome de la queue de cheval, une imagerie par resonance magnetique medullaire est realisee, n’expliquant pas la symptomatologie. En moins d’une semaine, sont apparus une paraplegie flasque et une paresie des membres superieurs. L’electromyogramme et la ponction lombaire objectivaient respectivement une polyradiculonevrite demyelinisante et une dissociation albumino-cytologique. Les cures d’immunoglobulines n’ont pas permis d’ameliorer le patient. Par la suite, la persistance d’un syndrome inflammatoire biologique, la degradation clinique du patient, l’apparition de lesions punctiformes ischemiques cerebrales et d’un hypersignal medullaire faisaient evoquer le diagnostic de lymphome endovasculaire. C’est finalement la biopsie neuromusculaire avec recherche de clonalite qui a permis de confirmer le diagnostic et de debuter un traitement par cyclophosphamide et methylprednisolone. Si cela a pu stopper l’aggravation, le handicap du patient est reste important. Discussion La confirmation anatomopathologique du lymphome endovasculaire est difficile a obtenir, souvent rendue en post-mortem, en raison de son pronostic sombre. La biopsie nerveuse et notamment la recherche de clonalite peut permettre de faire le diagnostic, d’ou la necessite de rechercher une atteinte neurologique peripherique clinique et electrophysiologique, meme si elle semble moins frequente que l’atteinte centrale. Conclusion Du fait de son accessibilite, la biopsie neuromusculaire est un examen cle du diagnostic de lymphome endovasculaire, en cas d’atteintes du systeme nerveux peripherique, tels que les Pseudo-Guillain Barre.

Published
2018
Full Text
View/download PDF

36. Real-life study of BRCA genetic screening in metastatic breast cancer

Author

Meynard, G., primary, Villanueva, C., additional, Thiery-Vuillemin, A., additional, Mansi, L., additional, Montcuquet, P., additional, Meneveau, N., additional, Chaigneau, L., additional, Bazan, F., additional, Almotlak, H., additional, Dobi, E., additional, Nguyen Tan Hon, T., additional, Klajer, E., additional, Fagnoni-Legat, C., additional, Paget-Bailly, S., additional, Meurisse, A., additional, Collonge-Rame, M-A., additional, Populaire-Ventron, C., additional, Pivot, X., additional, and Curtit, E., additional

Published
2017
Full Text
View/download PDF

39. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group Results

Author

P. Fumoleau, M.-J. Goudier, Philippe Montcuquet, Henri Roché, P. Kerbrat, Pascale Romestaing, Elisabeth Luporsi, Moïse Namer, P. Fargeot, Jacques Bonneterre, and A. Monnier

Subjects
Adult, medicine.medical_specialty, Time Factors, Cyclophosphamide, medicine.medical_treatment, Breast Neoplasms, Gastroenterology, Disease-Free Survival, Ventricular Dysfunction, Left, Breast cancer, Risk Factors, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Aged, Epirubicin, Retrospective Studies, Chemotherapy, business.industry, Cumulative dose, Incidence, Heart, Hematology, Middle Aged, medicine.disease, Chemotherapy regimen, Surgery, Radiation therapy, Treatment Outcome, Oncology, Chemotherapy, Adjuvant, Fluorouracil, Female, business, medicine.drug
Abstract

The aim of the study was to evaluate and compare incidence and risk factors of left ventricular dysfunction (LVD) in early breast cancer patients receiving (E+) or not (E-) epirubicin-based adjuvant chemotherapy.Among eight FASG trials, 3577 assessable patients were analyzed retrospectively: 2553 received epirubicin, 662 received hormonotherapy alone and 362 had no systemic treatment. Chemotherapy was FEC regimen in 86% of cases (fluorouracil, epirubicin, cyclophosphamide). Epirubicin cumulative dose was300 mg/m2 in 1040 patients, 300-600 in 1155,or = 600 in 279, followed by radiotherapy in 96% of cases.Twenty delayed LVD occurred: two in E- patients and 18 in E+ patients. In E+ patients, 14 patients normalized their cardiac function or did not require further investigations, one patient was stabilized with specific treatment, two patients worsened their functions and one died of congestive heart failure. The 7-year risk of LVD was 1.36% (95% CI 0.85-1.87) in E+ patients and 0.21% (95%CI: 0.00-0.52) in E- patients (P = 0.004). Two significant risk factors were identified: ageor = 65 years and body mass index27 kg/m2.After a long-term follow-up, epirubicin-related LVD risk was acceptable (1.36%) with one toxic death (0.04%). In 78% of cases, LVD were transient or well controlled.

Published
2006
Full Text
View/download PDF

40. Real-life study of BRCA genetic screening in metastatic breast cancer

Author

Laura Mansi, C. Populaire-Ventron, T. Nguyen Tan Hon, Elsa Curtit, Antoine Thiery-Vuillemin, Hamadi Almotlak, Philippe Montcuquet, G. Meynard, Cristian Villanueva, C. Fagnoni-Legat, Sophie Paget-Bailly, N. Meneveau, Fernando Bazan, Loic Chaigneau, Xavier Pivot, Erion Dobi, Elodie Klajer, M-A. Collonge-Rame, and Aurélia Meurisse

Subjects
Oncology, medicine.medical_specialty, business.industry, Internal medicine, medicine, Hematology, Life study, business, medicine.disease, Metastatic breast cancer
Published
2017
Full Text
View/download PDF

41. Phase II study of vinorelbine in patients with androgen-independent prostate cancer

Author

A. Caty, A. Monnier, X. Sun, F. Rolland, Yves Humblet, Roland Bugat, Martine Piccart, J. Breza, P. Houyau, Stéphane Oudard, T. Gil, J. Novak, D. Chopin, Marc Beauduin, E. Suc, P. Montcuquet, and Pierre Fumoleau

Subjects
Male, medicine.medical_specialty, Neutropenia, medicine.medical_treatment, Population, Phases of clinical research, Adenocarcinoma, Vinblastine, Vinorelbine, Gastroenterology, Disease-Free Survival, Drug Administration Schedule, Prostate cancer, Internal medicine, medicine, Humans, Neoplasm Metastasis, Bone pain, education, Aged, Pain Measurement, Aged, 80 and over, Chemotherapy, education.field_of_study, business.industry, Prostatic Neoplasms, Leukopenia, Hematology, Middle Aged, Prostate-Specific Antigen, medicine.disease, Antineoplastic Agents, Phytogenic, Surgery, Prostate-specific antigen, Oncology, Androgens, Quality of Life, Hormonal therapy, medicine.symptom, business, medicine.drug
Abstract

Summary Purpose To evaluate the efficacy and toxicity of vinorelbine in a phase ll study in patients with progressive metastatic andro-gen-independent prostate cancer. Patients and methods Forty-seven men with progressive metastatic prostate cancer refractory to first-line or second-line hormonal therapy were treated with vinorelbine, a semi-synthetic vinca-alkaloid. Vinorelbine was given, on an outpatient schedule, at 25 mg/m2 weekly for at least eight weeks or until progression or excessive toxicity. Results Forty-seven patients were included in the study, 33 being evaluable for tumour response, 36 for response to PSA, 21 for clinical benefit and 45 for toxicity. Median actual weekly dose was 19 mg/m2 (range 12.0–26.2 mg/m2). Six of thirty-six patients (17%) demonstrated a biologic response with a 50% or more decline in serum PSA on two consecutive measurements taken at least two weeks apart. The median duration of biologic response was 2.7 months. Two of three patients with measurable disease obtained an objective response but remained unconfirmed. No change disease was reported in 23 patients (49%). On entry into the study, 30 patients had symptomatic bone pain and required narcotic or non-narcotic analgesics. Clinical benefit from vinorelbine was achieved in 15 patients out of 21 (32% of the intent to treat analysis population and 71% of the assessable patients). Due to the low number of questionnaires (QLQ-C30) filled in, it was insufficient to allow any statistical analysis. The median survival was 10.2 months. Toxicity was mainly haematologic with 51% of patients experiencing grade 3 or 4 granulocytopenia. Three patients developed deep vein thrombosis. Non-haematologic toxicity, mainly nausea and neurotoxicity, was mild. Conclusions The administration of weekly vinorelbine appears to be a safe treatment for those patients with androgen-independent prostate cancer and poor prognosis features who require chemotherapy. These results provide data for future investigation of vinorelbine in combination regimens.

Published
2001
Full Text
View/download PDF

42. Surf: Open label, randomized multi-centre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma (mRCC)

Author

Mouillet, G., primary, Maurina, T., additional, Paillard, M.-J., additional, Montcuquet, P., additional, Hon, T. Nguyen Tan, additional, Almotlak, H., additional, Stein, U., additional, Berthod, D., additional, Robert, E., additional, Meurisse, A., additional, Bonnetain, F., additional, and Thiery-Vuillemin, A., additional

Published
2016
Full Text
View/download PDF

43. Prévalence et prise en charge de la douleur chez les patients présentant un cancer métastatique en Franche-Comté

Author

Dénommé, Fanny, primary, Kroemer, Marie, additional, Montcuquet, Philippe, additional, Nallet, Gilles, additional, Thiery-Vuillemin, Antoine, additional, Bazan, Fernando, additional, Mouillet, Guillaume, additional, Villanueva, Cristian, additional, Demarchi, Martin, additional, Stein, Ulrich, additional, Almotlak, Hamadi, additional, Chaigneau, Loïc, additional, Curtit, Elsa, additional, Meneveau, Nathalie, additional, Maurina, Tristan, additional, Dobi, Erion, additional, Hon, Thierry Nguyen Tan, additional, Cals, Laurent, additional, Mansi, Laura, additional, Verlut, Clotilde, additional, Pana-Katatali, Héloïse, additional, Caubet, Mathieu, additional, Paillard, Marie-Justine, additional, Limat, Samuel, additional, Pivot, Xavier, additional, and Nerich, Virginie, additional

Published
2016
Full Text
View/download PDF

44. Interleukin-15-Dependent T-Cell-like Innate Intraepithelial Lymphocytes Develop in the Intestine and Transform into Lymphomas in Celiac Disease

Author

Ettersperger, Julien, primary, Montcuquet, Nicolas, additional, Malamut, Georgia, additional, Guegan, Nicolas, additional, Lopez-Lastra, Silvia, additional, Gayraud, Ségolène, additional, Reimann, Christian, additional, Vidal, Elodie, additional, Cagnard, Nicolas, additional, Villarese, Patrick, additional, Andre-Schmutz, Isabelle, additional, Gomes Domingues, Rita, additional, Godinho-Silva, Cristina, additional, Veiga-Fernandes, Henrique, additional, Lhermitte, Ludovic, additional, Asnafi, Vahid, additional, Macintyre, Elizabeth, additional, Cellier, Christophe, additional, Beldjord, Kheira, additional, Di Santo, James P., additional, Cerf-Bensussan, Nadine, additional, and Meresse, Bertrand, additional

Published
2016
Full Text
View/download PDF

46. Surf: Open label, randomized multi-centre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma (mRCC)

Author

U. Stein, Hamadi Almotlak, D. Berthod, G. Mouillet, Philippe Montcuquet, Tristan Maurina, M.-J. Paillard, T. Nguyen Tan Hon, Aurélia Meurisse, E. Robert, F. Bonnetain, and Antoine Thiery-Vuillemin

Subjects
Oncology, medicine.medical_specialty, Sunitinib, business.industry, Phases of clinical research, Hematology, medicine.disease, Surgery, Regimen, Tolerability, Renal cell carcinoma, Internal medicine, medicine, In patient, Multi centre, business, Dose Modification, medicine.drug
Published
2016
Full Text
View/download PDF

47. L’encéphalopathie hyperammoniémique sous acide valproïque. Difficultés diagnostiques et thérapeutiques

Author

Alexis Montcuquet, Philippe Couratier, Bertrand Godet, and Hélène Combres

Subjects
Neurology, Neurology (clinical)
Abstract

Introduction L’encephalopathie hyperammoniemique (EH) sous acide valproique (VPA) est un effet indesirable classique mais rare. L’EH est secondaire a une perturbation du cycle de l’uree par competition sur le transporteur L-carnitine. Observation Une patiente de 50 ans, ethylique chronique non cirrhotique etait suivie pour une epilepsie depuis l’enfance sous phenobarbital (PHB) et VPA dont la dose avait ete recemment augmentee. Apres plusieurs episodes confusionnels regressifs inexpliques, la patiente est hospitalisee en reanimation devant un etat comateux. L’alcoolemie etait a 0,6 g/L. Le bilan biologique retrouvait une hyperammoniemie et une hyperlactatemie. Il n’etait pas retrouve de perturbation du bilan hepatique et les serologies virales etaient negatives. L’electroencephalogramme retrouvait des ondes lentes triphasiques anterieures. Le taux sanguin de VPA etait sous dosee et le PHB etait en zone therapeutique. L’evolution a ete favorable sous lactulose et L-carnitine. Un patient de 23 ans, suivi pour une sclerose tubereuse de Bourneville compliquee d’une epilepsie severe traite par VPA, lamotrigine et vigabatrin. Le patient a ensuite beneficie d’une association VPA et topiramate. Devant l’apparition d’un ralentissement psychomoteur important, le patient a ete hospitalise. Il a ete retrouve une hyperammoniemie. Devant l’efficacite de cette association et la stabilisation de l’etat clinique par la prescription au long cours de L-carnitine et lactulose, le traitement par VPA a pu etre continue. Discussion L’EH n’est pas dependante du taux plasmatique de VPA. Elle apparait plutot au debut du traitement, a l’augmentation de la posologie et est favorisee par des hepatopathies ou par certaines associations notamment avec le topiramate. Si le traitement par L-carnitine a la phase aigue semble consensuel, qu’en est-il de leur poursuite lorsque le traitement par VPA semble difficile a interrompre ? Conclusion Il est important d’evoquer rapidement l’EH car une prise en charge precoce est de pronostic favorable. Un traitement au long cours par L-carnitine pourrait permettre de poursuivre le VPA.

Published
2016
Full Text
View/download PDF

50. Efficacité, tolérance et coût de l’éribuline chez des patientes présentant un cancer du sein métastatique

Author

Paillard, Marie-Justine, primary, Curtit, Elsa, additional, Dobi, Erion, additional, Mansi, Laura, additional, Bazan, Fernando, additional, Villanueva, Cristian, additional, Chaigneau, Loïc, additional, Montcuquet, Philippe, additional, Meneveau, Nathalie, additional, Thiery-Vuillemin, Antoine, additional, Nerich, Virginie, additional, and Pivot, Xavier, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results